Insights

Gathering insights about NRI…

Similar companies to NRI

NRI Tech Stack

NRI uses 8 technology products and services including Font Awesome, imagesLoaded, Google Maps, and more. Explore NRI's tech stack below.

Font Awesome
Font Scripts
imagesLoaded
Javascript Libraries
Google Maps
Maps
Priority Hints
Performance
PHP
Programming Languages
reCAPTCHA
Security
ZURB Foundation
UI Frameworks
Gravity Forms
Web Platform Extensions

Media & News

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board's research, drug development and commercialization expertise Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board's research, drug development and commercialization expertise
Nov 10, 2025 | www.globenewswire.com
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and immune disorders, today announced the presentation of new translational data from its ongoing Phase 1 study of NX-1607, an oral, first-in-class inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting which is being held November 5–9, 2025, in National Harbor, MD. The poster, titled Translational Insights from a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors, expands upon data presented at the recent European Society for Medical Oncology (ESMO) Congress from heavily pretreated patients with a variety of tumor types who were treated with NX-1607 in an ongoing Phase 1a clinical trial.
Nov 07, 2025 | www.globenewswire.com
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced that updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial have been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6 – 9, 2025, in Orlando, Florida. The data will be featured in two presentations: an oral presentation with new results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and a poster presentation with updated results in patients with Waldenström macroglobulinemia.
Nov 03, 2025 | www.globenewswire.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D.
Oct 30, 2025 | www.globenewswire.com
Sumitomo Mitsui Trust Group Inc. Acquires 635,668 Shares of Nurix Therapeutics, Inc. $NRIX
Sumitomo Mitsui Trust Group Inc. lifted its holdings in Nurix Therapeutics, Inc. (NASDAQ: NRIX) by 84.1% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,391,638 shares of the company's stock after acquiring an additional 635,668 shares during the
Oct 30, 2025 | www.defenseworld.net
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the closing of its previously announced underwritten registered offering of 24,485,799 shares of its common stock at a purchase price of $10.21 per share. The gross proceeds to Nurix from the offering were $250.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix.
Oct 27, 2025 | www.globenewswire.com
Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript
Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs October 22, 2025 8:00 AM EDT Company Participants Arthur Sands - CEO, President & Director Paula O'Connor - Chief Medical Officer Gwenn Hansen - Chief Scientific Officer Johannes Van Houte - Chief Financial Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Gil Blum - Needham & Company, LLC, Research Division Matthew Biegler - Oppenheimer & Co. Inc., Research Division Joseph Catanzaro Brian Abrahams - RBC Capital Markets, Research Division Sudan Loganathan - Stephens Inc., Research Division Alexander Barenklau - Barclays Bank PLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Jeet Mukherjee - BTIG, LLC, Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Presentation Arthur Sands CEO, President & Director Good morning, and welcome to the Nurix Therapeutics Conference Call.
Oct 22, 2025 | seekingalpha.com

NRI's Email Address Formats

NRI uses at least 2 format(s):

NRI Email Formats	Example	Percentage
FLast@nri-2.com	JDoe@nri-2.com	73%
Last@nri-2.com	Doe@nri-2.com	14%
FirstLast@nri-2.com	JohnDoe@nri-2.com	13%
FLast@nriusa.com	JDoe@nriusa.com	100%

Frequently Asked Questions

Where is NRI's headquarters located?

NRI's main headquarters is located at 23475 Rock Haven Way, Suite 135 Sterling, Virginia 20166, US. The company has employees across 5 continents, including AsiaNorth AmericaAfrica.

What is NRI's stock symbol?

NRI is a publicly traded company; the company's stock symbol is NRIX.

What is NRI's official website and social media links?

NRI's official website is nriusa.com and has social profiles on LinkedIn.

What is NRI's NAICS code?

NRI's NAICS code is 23 - Construction.

How many employees does NRI have currently?

As of October 2025, NRI has approximately 61 employees across 5 continents, including AsiaNorth AmericaAfrica. Key team members include Vice President Operations: S. W.Manager: B. S.Service Manager: J. T.. Explore NRI's employee directory with LeadIQ.

What industry does NRI belong to?

NRI operates in the Construction industry.

What technology does NRI use?

NRI's tech stack includes Font AwesomeimagesLoadedGoogle MapsPriority HintsPHPreCAPTCHAZURB FoundationGravity Forms.

What is NRI's email format?

NRI's email format typically follows the pattern of FLast@nri-2.com. Find more NRI email formats with LeadIQ.

When was NRI founded?

NRI was founded in 1974.

NRI

Q: What is NRI's official website and social media links?

NRI's official website is nriusa.com. NRI has social profiles on LinkedIn.

Q: How many employees does NRI have currently?

NRI has approximately 61 employees.

Q: What technology does NRI use?

NRI's tech stack includes X-UA-Compatible, Google Analytics, Slider Revolution, JSON-LD, Google Tag Manager.

ConstructionUnited States51-200 Employees

An employee-owned company dedicated to creating value for our refrigeration and HVAC customers by providing quality solution-based results in service, installation, and maintenance.

Company Overview

Headquarters: 23475 Rock Haven Way, Suite 135 Sterling, Virginia 20166, US
Website: nriusa.com
Stock Symbol: NRIX
NAICS Code: 23 - Construction
Founded: 1974
Employees: 51-200

Media & News

Funding & Financials

$1M$10M
NRI's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
NRI's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to NRI

Kintetsu World Express

JAS Worldwide

Cogoport

Convoy Supply

Arrow Electronics

City of Davenport

Manuchar

IEH Corporation

The Crosby Group

Savi Technology

NRI Tech Stack

Media & News

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Sumitomo Mitsui Trust Group Inc. Acquires 635,668 Shares of Nurix Therapeutics, Inc. $NRIX

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript

NRI's Email Address Formats

Frequently Asked Questions

Where is NRI's headquarters located?

What is NRI's stock symbol?

What is NRI's official website and social media links?

What is NRI's NAICS code?

How many employees does NRI have currently?

What industry does NRI belong to?

What technology does NRI use?

What is NRI's email format?

When was NRI founded?

NRI

Company Overview

Media & News

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?